PCM
ANGO icon

Portolan Capital Management’s AngioDynamics ANGO Stock Holding History

Portolan Capital Management’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-193,416
Closed -$3.31M – 119
2017
Q3 		$3.31M Buy
+193,416
New +$3.25M 0.39% 80

Other funds holding ANGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Portolan Capital Management's ANGO Position: Q4 2017 in Review

Portolan Capital Management sold out of AngioDynamics (ANGO) in Q4 2017, closing a stake of 193,416 shares — an estimated $3.31M sold.

Portolan Capital Management first reported a position in ANGO in Q3 2017 and held it in 1 quarter. The position peaked at $3.31M in Q3 2017. 169 funds tracked by Wall St. Rank hold ANGO as of Q4 2017.

  • Portolan Capital Management reported no remaining AngioDynamics position as of Q4 2017 after selling out during the quarter.
  • Portolan Capital Management sold 193,416 AngioDynamics shares in Q4 2017, an estimated $3.31M.
  • Portolan Capital Management first reported a position in AngioDynamics in Q3 2017 and held it in 1 quarter.
  • Portolan Capital Management's AngioDynamics position peaked at $3.31M in Q3 2017.
  • 169 funds tracked by Wall St. Rank held AngioDynamics as of Q4 2017.

Based on Portolan Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.